Fezolinetant (Veoza) for Menopause Vasomotor Symptoms

NICE Technology Appraisals

Published March 31st, 2026

Detected March 31st, 2026

Summary

NICE published technology appraisal guidance TA1143 recommending fezolinetant (Veoza) as an option for treating moderate to severe vasomotor symptoms associated with menopause. The guidance applies to women who have had a breast cancer diagnosis where hormone replacement therapy is contraindicated. NHS commissioners must make funding available within 3 months of publication date.

View original document View source feed page

What changed

NICE issued final guidance TA1143 recommending fezolinetant (Veoza), a neurokinin B (NKB) receptor antagonist, for NHS use in England for treating moderate to severe vasomotor symptoms (hot flashes and night sweats) of the menopause. The technology is specifically recommended for women who have had a breast cancer diagnosis where HRT is contraindicated. The guidance number is TA1143 and was published on 31 March 2026.

Healthcare professionals should consider this new treatment option when treating eligible patients with menopause vasomotor symptoms. Commissioners and providers have a responsibility to provide funding to enable the guidance to be applied when health professionals and patients wish to use it, typically within 3 months of publication. The guidance will be reviewed if new evidence emerges that is likely to change the recommendations.

What to do next

Review treatment protocols for menopause vasomotor symptoms to incorporate fezolinetant as an option for eligible patients
Ensure commissioning and funding pathways are in place for prescribing fezolinetant (Veoza) to appropriate patients
Report any adverse events related to fezolinetant using the Yellow Card Scheme to the MHRA

Source document (simplified)

Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause

Technology appraisal guidance
TA1143
Published:

31 March 2026

Download guidance (PDF)

Overview

Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.

Last reviewed: 31 March 2026

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Guidance development process

How we develop NICE technology appraisal guidance

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.